Merck & Co. and Schering-Plough Corp. currently face around 140 Vytorin class action lawsuits involving their once-popular cholesterol drug, which has been shown to provide no medical benefits over cheaper generic alternatives. In addition, this week the drug makers disclosed that the U.S. Department of Justice is now investigating their marketing of the medication. Continued
All Posts Tagged With: "Cancer"
Researcher Claims “No Credible Evidence” of Vytorin Cancer Side Effects
In response to concerns about a potential link between Vytorin and cancer, the FDA has initiated a safety review and members of Congress have requested additional information about the potential side effect. However, a prominent researcher released a letter this week in response to the congressional probe indicating that there is “no credible evidence” that Vytorin is linked to an increased risk of cancer. Continued
NEJM: Too Soon To Dismiss Vytorin Cancer Connection
According to an editorial published in the New England Journal of Medicine, it is too early to rule out concerns about a possible Vytorin cancer connection that was identified in recent study data. The makers of Vytorin had previously sent a letter to healthcare providers dismissing the findings as likely attributed to chance. Continued
Humira Lawsuits
The arthritis drug Humira has been linked to a number of serious and potentially life threatening infections, including potentially fatal fungal infections. Continued
Remicade Lawsuits
The arthritis drug Remicade has been linked to a number of serious and potentially life threatening injuries. In September 2008, stronger warnings were added about an increased risk of invasive fungal infections. Continued
Enbrel Lawsuits
The arthritis drug Enbrel has been linked to an increased risk of fatal infections, incluing tuberculosis and fungal infections. In May 2008, a “black box” warning was added about the risk of tuberculosis. In September 2008, the FDA added information to the “black box” warning about the risk of potentially fatal fungal infections, which were often going undiagnosed. Continued
FDA Investigating Link between Vytorin and Cancer
The FDA released an early communication yesterday, about an investigation into the possible association between cancer and Vytorin, Zetia and Zocor. Continued
Vytorin Cancer Risk Dismissed by Drug Makers
Merck & Co. and Schering Plough Corp., the joint marketers of the cholesterol drug Vytorin, have sent a letter to healthcare providers dismissing the potential increased risk of cancer identified in a recent study. The drug makers indicate that the higher incidence of cancer seen among users of Vytorin in the study is likely attributed to chance. Continued
FDA Highlights Regranex Foot Ulcer Gel Cancer Warnings
On Friday, the FDA announced a new “black box” warning for Johnson & Johnson’s Regranex foot gel. The prescription topical cream is used by diabetics to treat leg and foot ulcers which are not healing. The warning indicates that when large amounts of Regranex are used, it could increase the risk of death from cancer. Continued
Regranex Lawsuits
Regranex Gel has been linked to a substantially increased risk of death from cancer when three or more tubes are used within 20 months to treat severe foot or leg ulcers in diabetics. In June 2008, the FDA announced a “black box” warning about the risk of cancer death as a possible side effect of Regranex. Continued
